Preoperative Hepatic Arterial Infusion Chemotherapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by IRCCS San Raffaele.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
IRCCS San Raffaele
ClinicalTrials.gov Identifier:
NCT00522509
First received: August 28, 2007
Last updated: NA
Last verified: May 2007
History: No changes posted
  Purpose

To assess the feasibility and results of liver resection after preoperative hepatic artery infusion (HAI) chemotherapy with FUDR.


Condition Intervention
Colorectal Liver Metastases
Drug: Floxuridine FUDR

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Preoperative Hepatic Arterial Infusion Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases

Resource links provided by NLM:


Further study details as provided by IRCCS San Raffaele:

Study Start Date: December 1995
Detailed Description:

Between 1995 and 2004, 239 patients with isolated colorectal liver metastases received HAI chemotherapy with neoadjuvant intent. Fifty of these patients underwent subsequent curative liver resection (HAI group).

Postoperative morbidity, liver function tests, and long term outcomes were evaluated. Adverse events related to HAI chemotherapy were also evaluated.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Unresectable liver metastases
  • Potentially resectable liver metastases

Exclusion Criteria:

  • Extrahepatic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00522509

Locations
Italy
Department of Surgery - Liver Unit, Scientific Institute San Raffaele,
Milan, Italy, 20132
Sponsors and Collaborators
IRCCS San Raffaele
Investigators
Principal Investigator: Luca Aldrighetti, M.D, PhD Department of Surgery - Liver Unit, Scientific Institute San Raffaele,
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00522509     History of Changes
Other Study ID Numbers: Neoadjuvant HAIC
Study First Received: August 28, 2007
Last Updated: August 28, 2007
Health Authority: Italy: Istituto Superiore di Sanità

Additional relevant MeSH terms:
Neoplasm Metastasis
Liver Neoplasms
Neoplastic Processes
Neoplasms
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Floxuridine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 08, 2014